About Atriva
Atriva Therapeutics stands for the next generation of antiviral therapies. MEK Inhibitors have high potential as truly efficacious and safe antiviral drugs to address the urgent need e.g. for a novel, broadly active influenza therapy.
Press releases
Press
HTGF portfolio company: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment
European Investment Bank and Atriva Therapeutics sign financing agreement of €24 million for the research, development and clinical testing of the company’s lead product candidate against influenza and COVID-19Atriva’s ATR-002 molecule is the only host-cell targeting antiviral therapeutic specifically developed to treat severe respiratory infections caused by RNA (ribonucleic acid) viruses – it may prevent progression to critical-stage COVID-19 in hospitalised patients and holds stro
Press
Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan
Round led by existing investors Meneldor and High-Tech GründerfondsProceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development in influenza and other respiratory viral infectionsATR-002 mode of action inhibits viral propagation of respiratory RNA viruses and prevents the cytokine storm, as demonstrated in preclinical studies
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral the
Press
Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage
The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical development stage.
Atriva Therapeutics stands for the next generation of
Info & Contact
- Dr. Rainer Lichtenberger, CEO
Address
Atriva Therapeutics GmbH
Eisenbahnstr. 1
72072 Tübingen
Eisenbahnstr. 1
72072 Tübingen
In portfolio
27. Dec 2016
Sector
Dr. Frank Hensel
Principal / Authorized signatory